PEB - Pacific Edge Ltd

[psychic]

The development to date for those who are just joining the thread.

http://www.clpmag.com/2015/01/abbott...cer-biomarker/

"Abbott currently offers the only FDA-approved urine-based molecular test for bladder cancer, UroVysion, which is included in the National Comprehensive Cancer Network and European Association of Urology guidelines.

The FGFR3 mutation analysis assay will be available in early 2015. Abbott is also in the process of developing reagents for further studies, and is exploring collaborations with pharmaceutical companies to leverage the FGFR3 test as a companion diagnostic for emerging bladder cancer therapies."

Just for those joining the thread..

Abbotts have the UroVysion test - which we know is expensive and inferior to CxBladder

They have acquired the exclusive rights to and will launch ANOTHER test based on FGFR3 gene mutation.

The use of FGFR3 mutation is not new and was part of the CertnDX test - which flopped under scrutiny of tighter CMS reiimbursement policy.

Activating FGFR3 gene mutations are seen in about 70% of low-grade and 15 to 20% of high-grade bladder cancer cases, making them useful biomarkers to assist in early detection.


Useful, perhaps. But how useful?

[nextbigthing]

10:00 The Moderators ban Minerbarejet & Balance for 3 days.

Dear MOD,

There's an interesting debate going on here and people who disagree are asking Balance for info etc which he can now no longer give. Sure some people need to watch how they say some things but blanket banning people whenever the debate gets a little heated is just frustrating and defeating the purpose of the forum.

If people don't like the way certain members post, let them block the member themselves.

Cheers,

Nextblockedthing

[Tsuba]

Cripes, hope this doesn t mean the death knoll for PEB...
Why oh why has it taken PEB so long to get to the FDA approval stage..

Was recently talking to a lady from the States who works in the pio tech world. FDA can take a long time to get for anyone.

[Dentie]

The development to date for those who are just joining the thread.

http://www.clpmag.com/2015/01/abbott...cer-biomarker/

"Abbott currently offers the only FDA-approved urine-based molecular test for bladder cancer, UroVysion, which is included in the National Comprehensive Cancer Network and European Association of Urology guidelines.

The FGFR3 mutation analysis assay will be available in early 2015. Abbott is also in the process of developing reagents for further studies, and is exploring collaborations with pharmaceutical companies to leverage the FGFR3 test as a companion diagnostic for emerging bladder cancer therapies."

Bingo! Here's the expected and belated attempt to regain some sincerity, respect and credibility amongst thread dwellers. 'On ya' Balance!

Now doesn't that feel better than slinging innuendo & teasing comment around - obviously with the prime & collusional intent of creating a stampede by the bulls?

[skid]

So we seem to have 2 schools of thought here--the first is that, with what many think is a superior product--that alone should be enough to attain a dominate place in the market and convert to sales(thus achieving the target)
The second,while still believing that the product is good,maybe superior, are concerned that that alone is not enough.-that partnering up with a large company that is already established in the market place,or at the very least,an aggressive marketing campaign is necessary in the real world of the US medical community.
The idea that they are up against a heavyweight such as abbot has alarmed those in the second camp-(they have concerns that a company with the clout of abbot can tip the level playing field in their favor,with sweeteners,discounts,a stable of other products to use as leverage,etc.)-those in the first camp are not particularly worried because they feel the product is good enough to sell itself especially if the running tests show its better.--those in the second camp feel time is ticking in terms of the budget. They feel that if PEB would have had the opportunity to team up with their own heavyweight,they would have done so (to distribute the product)an example of this is PEB being distributed by Oryzon, in Spain and Portugal.
The first school feels that PEB have intentionally chosen to go it alone in the States(rather than their strategy in Spain and Portugal)
Have I missed anything?

[skid]

well done skid....... just 2 more things to add to the picture for consideration....
current sales results for PEB continue to emulate the sales curve of nmp22...... this gives weight to the fact that just having a better product does not necessarily mean more sales.
Also it needs to be considered that there are at least 4 bladder cancer bio marker test that have now partnered up with giant healthcare JV partners to help push their products into the market.

One has to wonder if PEB product is so good/superior why did they get turned away from large pharmaceutical companies that are actively in the market buying marketable healthcare products.
More directly why are other bio marker products finding it easy to partner up with the big boys and PEB is being left out in the cold.
It is not from choice that PEB went on a lone path as they have openly admitted that they were turned away from the big boys.
Honestly the investment alarm bells should be ringing.

I suppose your first thought could be an elaboration on the ''Is the product enough''? category -- cheers.

second thought was touched on

I suppose another consideration would be whether PEB is an attractive target for a buy out,and whether this would benefit shareholders. (which is another whole area of debate)

[MAC]

Despite contrary belief by some, large or small companies and corporations don’t make large investments just for the hell of it.

Those of us who have prepared and presented board proposals know that well, especially at question time, so heres a proposal for a would be entrant to the market;

Mr Chairman, we’ve just spent $20M in the lab working up a bladder cancer diagnostic test, we think it’s great, it’s got 89% T1 sensitivity, it’s not as good as cytology and there’s already a company that can do 100% in the market with Cxbladder, wow those guys are good and they’re three years ahead, but we’ve had fun strutting about in the lab and in the media too, now we want $60M more to commercialise it, and our mate Moosie thinks we should do it just for ****s and giggles, what do ya reckon Mr Chairman ?

The medical sector is very large and expanding and there are a lot’s of opportunities out there, companies invest their cash where they have the best likelihood of success, not into a space that is already being occupied by something better.

When it comes to the crunch, those with inferior products waiver when it comes to shaky hands committing large sums of money, particularly so when they can invest that cash elsewhere with a better product.

It is hard to beat 100%.

[skid]

companies invest their cash where they have the best likelihood of success, Quote

If this is the case then i am puzzled why Abbot has chosen to throw some serious money at this --someone may have been mistaken in their assumptions

Perhaps we should say - companies invest where they THINK they have the best likely hood of success

It still comes down to ---- product vs product+marketing --- or perhaps I should say- -- product(that markets itself) vs product+marketing

[skid]

It would be interesting to know if the big insurance providers always go for the best products or the less amiable path of a cheaper option either directly or indirectly.

[MAC]

And, then there’s this interesting misnomer about distribution channels and some large pharma corporations being better able to distribute. Conceptually, probably is so for companies selling frozen veges into supermarkets.

There are only 9,000 urologists in the US, and predominantly they are represented by just a handful of regional large urology groups (LUGs) and just a few healthcare management organisations (HMOs).

I’m sure Pacific Edge with their 19 sales regions and 12 strategic sales staff, now they have been hired, will be working with them all right about now in making recognition of this new disruptive technology that is Cxbladder.

And of course many might consider those enviable distribution channels to be the national network providers (NPNs), oh yeah, they’re the ones which Pacific Edge have recently signed up with and have agreed commercial terms and price points with.

It’s a five year plan to achieve a 10% market share, they are two years ahead of any real possible competition and although every company needs to be on its toes, adaptable, and pushing ahead, they’re generally doing a pretty fine job in commercialising their Cxbladder test thus far IMO.